{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:11:31Z","timestamp":1791141091147,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072813"],"award-info":[{"award-number":["82072813"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203557"],"award-info":[{"award-number":["82203557"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103358"],"award-info":[{"award-number":["82103358"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Science and Technology Development Fund (FDCT) of Macau SAR"},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515110792"],"award-info":[{"award-number":["2020A1515110792"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515010342"],"award-info":[{"award-number":["2022A1515010342"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515110640"],"award-info":[{"award-number":["2020A1515110640"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515011290"],"award-info":[{"award-number":["2020A1515011290"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202201010053"],"award-info":[{"award-number":["202201010053"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The therapeutic efficacy of metformin in prostate cancer (PCa) appears uncertain based on various clinical trials. Metformin treatment failure may be attributed to the high frequency of transcriptional dysregulation, which leads to drug resistance. However, the underlying mechanism is still unclear. In this study, we found evidences that metformin resistance in PCa cells may be linked to cell cycle reactivation. Super-enhancers (SEs), crucial regulatory elements, have been shown to be associated with drug resistance in various cancers. Our analysis of SEs in metformin-resistant (MetR) PCa cells revealed a correlation with Prostaglandin Reductase 1 (PTGR1) expression, which was identified as significantly increased in a cluster of cells with metformin resistance through single-cell transcriptome sequencing. Our functional experiments showed that PTGR1 overexpression accelerated cell cycle progression by promoting progression from the G0\/G1 to the S and G2\/M phases, resulting in reduced sensitivity to metformin. Additionally, we identified key transcription factors that significantly increase PTGR1 expression, such as SRF and RUNX3, providing potential new targets to address metformin resistance in PCa. In conclusion, our study sheds new light on the cellular mechanism underlying metformin resistance and the regulation of the SE-TFs-PTGR1 axis, offering potential avenues to enhance metformin\u2019s therapeutic efficacy in PCa.<\/jats:p>","DOI":"10.1038\/s41392-023-01516-2","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:01:51Z","timestamp":1692144111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Metformin escape in prostate cancer by activating the PTGR1 transcriptional program through a novel super-enhancer"],"prefix":"10.1038","volume":"8","author":[{"given":"Jianheng","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanghua","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfa","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiduan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3794-641X","authenticated-orcid":false,"given":"Jianming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangjia","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingke","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjiang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-111X","authenticated-orcid":false,"given":"Yanqiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huichan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaodong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1428-904X","authenticated-orcid":false,"given":"Zhenyu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weide","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"1516_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7\u201333 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"1516_CR2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3322\/caac.21565","volume":"69","author":"KD Miller","year":"2019","unstructured":"Miller, K. D. et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin. 69, 363\u2013385 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"1516_CR3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen, P. L. et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur. Urol. 67, 825\u2013836 (2015).","journal-title":"Eur. Urol."},{"key":"1516_CR4","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/med.21766","volume":"41","author":"HJ Cardoso","year":"2021","unstructured":"Cardoso, H. J. et al. Revisiting prostate cancer metabolism: from metabolites to disease and therapy. Med. Res. Rev. 41, 1499\u20131538 (2021).","journal-title":"Med. Res. Rev."},{"key":"1516_CR5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fphys.2017.00097","volume":"8","author":"F Cutruzzol\u00e0","year":"2017","unstructured":"Cutruzzol\u00e0, F. et al. Glucose metabolism in the progression of prostate cancer. Front. Physiol. 8, 97 (2017).","journal-title":"Front. Physiol."},{"key":"1516_CR6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41391-018-0085-2","volume":"22","author":"S Zaidi","year":"2019","unstructured":"Zaidi, S. et al. The anticancer potential of metformin on prostate cancer. Prostate Cancer Prostatic Dis. 22, 351\u2013361 (2019).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1516_CR7","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.tips.2020.09.001","volume":"41","author":"L He","year":"2020","unstructured":"He, L. Metformin and systemic metabolism. Trends Pharmacol. Sci. 41, 868\u2013881 (2020).","journal-title":"Trends Pharmacol. Sci."},{"key":"1516_CR8","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.tips.2018.07.006","volume":"39","author":"A Vancura","year":"2018","unstructured":"Vancura, A. et al. Metformin as an anticancer agent. Trends Pharmacol. Sci. 39, 867\u2013878 (2018).","journal-title":"Trends Pharmacol. Sci."},{"key":"1516_CR9","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature13270","volume":"510","author":"AK Madiraju","year":"2014","unstructured":"Madiraju, A. K. et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542\u2013546 (2014).","journal-title":"Nature"},{"key":"1516_CR10","doi-asserted-by":"crossref","first-page":"8540","DOI":"10.3390\/ijms21228540","volume":"21","author":"HK Ahn","year":"2020","unstructured":"Ahn, H. K., Lee, Y. H. & Koo, K. C. Current status and application of metformin for prostate cancer: a comprehensive review. Int. J. Mol. Sci. 21, 8540 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1516_CR11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2012.12.004","volume":"63","author":"DE Spratt","year":"2013","unstructured":"Spratt, D. E. et al. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur. Urol. 63, 709\u2013716 (2013).","journal-title":"Eur. Urol."},{"key":"1516_CR12","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/annonc\/mdw410","volume":"27","author":"C Coyle","year":"2016","unstructured":"Coyle, C., Cafferty, F. H., Vale, C. & Langley, R. E. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann. Oncol. 27, 2184\u20132195 (2016).","journal-title":"Ann. Oncol."},{"key":"1516_CR13","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2012.46.7043","volume":"31","author":"D Margel","year":"2013","unstructured":"Margel, D. et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J. Clin. Oncol. 31, 3069\u20133075 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1516_CR14","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.eururo.2014.04.027","volume":"66","author":"MA Preston","year":"2014","unstructured":"Preston, M. A. et al. Metformin use and prostate cancer risk. Eur. Urol. 66, 1012\u20131020 (2014).","journal-title":"Eur. Urol."},{"key":"1516_CR15","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1007\/s00125-012-2653-7","volume":"55","author":"RJ Stevens","year":"2012","unstructured":"Stevens, R. J. et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 55, 2593\u20132603 (2012).","journal-title":"Diabetologia"},{"key":"1516_CR16","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/jnci\/djt170","volume":"105","author":"D Margel","year":"2013","unstructured":"Margel, D. et al. Association between metformin use and risk of prostate cancer and its grade. J. Natl. Cancer Inst. 105, 1123\u20131131 (2013).","journal-title":"J. Natl. Cancer Inst."},{"key":"1516_CR17","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1158\/1055-9965.EPI-14-0056","volume":"23","author":"L Bensimon","year":"2014","unstructured":"Bensimon, L. et al. The use of metformin in patients with prostate cancer and the risk of death. Cancer Epidemiol. Biomark. Prev. 23, 2111\u20132118 (2014).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1516_CR18","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.2337\/dc14-0584","volume":"37","author":"KK Tsilidis","year":"2014","unstructured":"Tsilidis, K. K. et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care 37, 2522\u20132532 (2014).","journal-title":"Diabetes Care"},{"key":"1516_CR19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/bcpt.12898","volume":"122","author":"MK Asiedu","year":"2018","unstructured":"Asiedu, M. K., Barron, M., Aubry, M. C. & Wigle, D. A. Patient- and cell type-specific heterogeneity of metformin response. Basic Clin. Pharmacol. Toxicol. 122, 214\u2013222 (2018).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"1516_CR20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.tips.2018.12.004","volume":"40","author":"A Recasens","year":"2019","unstructured":"Recasens, A. & Munoz, L. Targeting cancer cell dormancy. Trends Pharmacol. Sci. 40, 128\u2013141 (2019).","journal-title":"Trends Pharmacol. Sci."},{"key":"1516_CR21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","volume":"20","author":"JC Marine","year":"2020","unstructured":"Marine, J. C., Dawson, S. J. & Dawson, M. A. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 20, 743\u2013756 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"1516_CR22","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","volume":"155","author":"D Hnisz","year":"2013","unstructured":"Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934\u2013947 (2013).","journal-title":"Cell"},{"key":"1516_CR23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Lov\u00e9n","year":"2013","unstructured":"Lov\u00e9n, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320\u2013334 (2013).","journal-title":"Cell"},{"key":"1516_CR24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13046-021-01974-y","volume":"40","author":"GH Li","year":"2021","unstructured":"Li, G. H. et al. Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance. J. Exp. Clin. Cancer Res. CR 40, 174 (2021).","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"1516_CR25","doi-asserted-by":"crossref","first-page":"6556","DOI":"10.1038\/s41388-020-01456-z","volume":"39","author":"S Wen","year":"2020","unstructured":"Wen, S. et al. Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer. Oncogene 39, 6556\u20136571 (2020).","journal-title":"Oncogene"},{"key":"1516_CR26","doi-asserted-by":"crossref","first-page":"107532","DOI":"10.1016\/j.celrep.2020.107532","volume":"31","author":"Q Ma","year":"2020","unstructured":"Ma, Q. et al. Super-enhancer redistribution as a mechanism of broad gene dysregulation in repeatedly drug-treated cancer cells. Cell Rep. 31, 107532 (2020).","journal-title":"Cell Rep."},{"key":"1516_CR27","volume":"11","author":"L Guo","year":"2020","unstructured":"Guo, L. et al. A combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells. Nat. Commun. 11, 740 (2020).","journal-title":"Nat. Commun."},{"key":"1516_CR28","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.4161\/cc.27982","volume":"13","author":"C Oliveras-Ferraros","year":"2014","unstructured":"Oliveras-Ferraros, C. et al. Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. Cell Cycle 13, 1132\u20131144 (2014).","journal-title":"Cell Cycle"},{"key":"1516_CR29","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1158\/0008-5472.CAN-10-1769","volume":"71","author":"I Ben Sahra","year":"2011","unstructured":"Ben Sahra, I. et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71, 4366\u20134372 (2011).","journal-title":"Cancer Res."},{"key":"1516_CR30","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1158\/0008-5472.CAN-19-2852","volume":"80","author":"J Xie","year":"2020","unstructured":"Xie, J. et al. GPD1 enhances the anticancer effects of metformin by synergistically increasing total cellular glycerol-3-phosphate. Cancer Res. 80, 2150\u20132162 (2020).","journal-title":"Cancer Res."},{"key":"1516_CR31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307\u2013319 (2013).","journal-title":"Cell"},{"key":"1516_CR32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.molcel.2020.04.010","volume":"78","author":"DC Levine","year":"2020","unstructured":"Levine, D. C. et al. NAD(+) controls circadian reprogramming through per2 nuclear translocation to counter aging. Mol. cell 78, 835\u2013849.e837 (2020).","journal-title":"Mol. cell"},{"key":"1516_CR33","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/ncb3210","volume":"17","author":"H Liu","year":"2015","unstructured":"Liu, H. et al. Redeployment of Myc and E2f1-3 drives Rb-deficient cell cycles. Nat. Cell Biol. 17, 1036\u20131048 (2015).","journal-title":"Nat. Cell Biol."},{"key":"1516_CR34","volume":"13","author":"J Koch","year":"2022","unstructured":"Koch, J. et al. Targeting the retinoblastoma\/E2F repressive complex by CDK4\/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus. Nat. Commun. 13, 4689 (2022).","journal-title":"Nat. Commun."},{"key":"1516_CR35","doi-asserted-by":"crossref","first-page":"717730","DOI":"10.3389\/fphar.2021.717730","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. Prostaglandin reductase 1 as a potential therapeutic target for cancer therapy. Front. Pharmacol. 12, 717730 (2021).","journal-title":"Front. Pharmacol."},{"key":"1516_CR36","first-page":"11481","volume":"47","author":"X Wang","year":"2019","unstructured":"Wang, X., Cairns, M. J. & Yan, J. Super-enhancers in transcriptional regulation and genome organization. Nucleic Acids Res. 47, 11481\u201311496 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1516_CR37","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31919-8","volume":"13","author":"MR Kelly","year":"2022","unstructured":"Kelly, M. R. et al. A multi-omic dissection of super-enhancer driven oncogenic gene expression programs in ovarian cancer. Nat. Commun. 13, 4247 (2022).","journal-title":"Nat. Commun."},{"key":"1516_CR38","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"1516_CR39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","volume":"18","author":"E Currie","year":"2013","unstructured":"Currie, E. et al. Cellular fatty acid metabolism and cancer. Cell Metab. 18, 153\u2013161 (2013).","journal-title":"Cell Metab."},{"key":"1516_CR40","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.eururo.2016.07.015","volume":"70","author":"S Gillessen","year":"2016","unstructured":"Gillessen, S. et al. Repurposing metformin as therapy for prostate cancer within the STAMPEDE trial platform. Eur. Urol. 70, 906\u2013908 (2016).","journal-title":"Eur. Urol."},{"key":"1516_CR41","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ccell.2019.03.007","volume":"35","author":"M Elgendy","year":"2019","unstructured":"Elgendy, M. et al. Combination of hypoglycemia and metformin impairs tumor metabolic plasticity and growth by modulating the PP2A-GSK3\u03b2-MCL-1 axis. Cancer Cell 35, 798\u2013815.e795 (2019).","journal-title":"Cancer Cell"},{"key":"1516_CR42","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1158\/0008-5472.CAN-21-1606","volume":"81","author":"N Wajapeyee","year":"2021","unstructured":"Wajapeyee, N. & Gupta, R. Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapies. Cancer Res. 81, 5589\u20135595 (2021).","journal-title":"Cancer Res."},{"key":"1516_CR43","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature07829","volume":"459","author":"ND Heintzman","year":"2009","unstructured":"Heintzman, N. D. et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459, 108\u2013112 (2009).","journal-title":"Nature"},{"key":"1516_CR44","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1126\/science.aaj2191","volume":"355","author":"I Levin-Reisman","year":"2017","unstructured":"Levin-Reisman, I. et al. Antibiotic tolerance facilitates the evolution of resistance. Science 355, 826\u2013830 (2017).","journal-title":"Science"},{"key":"1516_CR45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharmthera.2019.02.014","volume":"199","author":"P Thandapani","year":"2019","unstructured":"Thandapani, P. Super-enhancers in cancer. Pharmacol. Ther. 199, 129\u2013138 (2019).","journal-title":"Pharmacol. Ther."},{"key":"1516_CR46","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ccr.2013.05.003","volume":"23","author":"A Roesch","year":"2013","unstructured":"Roesch, A. et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 23, 811\u2013825 (2013).","journal-title":"Cancer Cell"},{"key":"1516_CR47","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","volume":"173","author":"C Kim","year":"2018","unstructured":"Kim, C. et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell 173, 879\u2013893.e813 (2018).","journal-title":"Cell"},{"key":"1516_CR48","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25624-1","volume":"12","author":"S Taavitsainen","year":"2021","unstructured":"Taavitsainen, S. et al. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. Nat. Commun. 12, 5307 (2021).","journal-title":"Nat. Commun."},{"key":"1516_CR49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14728222.2022.2032652","volume":"26","author":"H Azam","year":"2022","unstructured":"Azam, H. et al. Emerging role for the Serum Response Factor (SRF) as a potential therapeutic target in cancer. Expert Opin. Ther. Targets 26, 155\u2013169 (2022).","journal-title":"Expert Opin. Ther. Targets"},{"key":"1516_CR50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrc3877","volume":"15","author":"Y Ito","year":"2015","unstructured":"Ito, Y., Bae, S. C. & Chuang, L. S. The RUNX family: developmental regulators in cancer. Nat. Rev. Cancer 15, 81\u201395 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"1516_CR51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.freeradbiomed.2016.11.027","volume":"102","author":"R S\u00e1nchez-Rodr\u00edguez","year":"2017","unstructured":"S\u00e1nchez-Rodr\u00edguez, R. et al. Ptgr1 expression is regulated by NRF2 in rat hepatocarcinogenesis and promotes cell proliferation and resistance to oxidative stress. Free Radic. Biol. Med. 102, 87\u201399 (2017).","journal-title":"Free Radic. Biol. Med."},{"key":"1516_CR52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5582\/bst.2016.01045","volume":"10","author":"L Xue","year":"2016","unstructured":"Xue, L. et al. Knockdown of prostaglandin reductase 1 (PTGR1) suppresses prostate cancer cell proliferation by inducing cell cycle arrest and apoptosis. Biosci. trends 10, 133\u2013139 (2016).","journal-title":"Biosci. trends"},{"key":"1516_CR53","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13046-021-01996-6","volume":"40","author":"R Liu","year":"2021","unstructured":"Liu, R. et al. A HIF1\u03b1-GPD1 feedforward loop inhibits the progression of renal clear cell carcinoma via mitochondrial function and lipid metabolism. J. Exp. Clin. Cancer Res. CR 40, 188 (2021).","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"1516_CR54","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.21037\/tau-21-400","volume":"10","author":"S Cai","year":"2021","unstructured":"Cai, S. et al. The prognostic roles of CYP19A1 expression in bladder cancer patients of different genders. Transl. Androl. Urol. 10, 3579\u20133590 (2021).","journal-title":"Transl. Androl. Urol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01516-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01516-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01516-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T09:05:11Z","timestamp":1700471111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01516-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1038\/s41392-023-01516-2","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,16]]},"assertion":[{"value":"2 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal experiments were performed in compliance with the guidelines of the Animal Ethics Committee at South China University of Technology (Guangzhou, Guangdong, China). All mice used in this study were housed under specific pathogen-free (SPF) conditions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"303"}}